Francesca Nacci

ORCID: 0000-0002-2558-9785
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Rheumatoid Arthritis Research and Therapies
  • Systemic Sclerosis and Related Diseases
  • Fibromyalgia and Chronic Fatigue Syndrome Research
  • Autoimmune and Inflammatory Disorders Research
  • Systemic Lupus Erythematosus Research
  • Spondyloarthritis Studies and Treatments
  • Musculoskeletal pain and rehabilitation
  • Dermatologic Treatments and Research
  • Inflammatory Myopathies and Dermatomyositis
  • Psoriasis: Treatment and Pathogenesis
  • Chronic Lymphocytic Leukemia Research
  • Monoclonal and Polyclonal Antibodies Research
  • Skin and Cellular Biology Research
  • Cytokine Signaling Pathways and Interactions
  • Biosimilars and Bioanalytical Methods
  • Dermatological and Skeletal Disorders
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Dupuytren's Contracture and Treatments
  • Health, psychology, and well-being
  • Lymphatic System and Diseases
  • Telemedicine and Telehealth Implementation
  • Immunodeficiency and Autoimmune Disorders
  • Health Systems, Economic Evaluations, Quality of Life
  • Tuberculosis Research and Epidemiology
  • Occupational Health and Performance

University of Florence
2014-2025

Azienda Ospedaliero-Universitaria Careggi
2014-2023

Scientific Research Institute of Experimental and Clinical Medicine
2014

Florence (Netherlands)
2006-2007

Center for Rheumatology
2006

To evaluate in SSc, the frequency of digital lesions and morphology, characteristics, natural course time to healing 1614 ulcers (DUs).One hundred SSc patients were followed up for 4 years. In first step, observed classified at presentation [digital pitting scar (DPS); DU; calcinosis; gangrene]. second DUs divided into subsets according their origin main features. third was recorded each DU influence characteristics on also evaluated.In observed: DPS, 712 (44.1%) lesions; DU, 785 (48.6%);...

10.1093/rheumatology/keq097 article EN Lara D. Veeken 2010-04-16

In systemic sclerosis (SSc), joint involvement may reduce the functional capacity of hands. Intravenous immunoglobulins have previously been shown to benefit patients with SSc.To verify efficacy intravenous on and function in SSc.7 women SSc, 5 limited 2 diffuse a severe refractory were enrolled study. Methotrexate cyclophosphamide pulse therapy did not ameliorate symptoms. Hence, was prescribed at dosage g/kg body weight during 4 days/month for six consecutive courses. The presence...

10.1136/ard.2006.060111 article EN Annals of the Rheumatic Diseases 2007-02-02

Objective. To identify the determinants of anti-TNF-naive patients' preferences for route administration anti-TNF agents. Methods. The study was carried out in 50 Italian rheumatology centres (802 patients). All patients completed a 31-item questionnaire addressing their perceptions current treatment and with Statistical methods included analysis variance (ANOVA), t-test chi-square test. Results. response rate to 97.6%. At time survey, 310 (39.9%) were dissatisfied treatments, owing...

10.1093/rheumatology/kep354 article EN Lara D. Veeken 2009-11-17

To establish optimal cut-off values for the scores of revised Fibromyalgia Impact Questionnaire (FIQR), modified Fibromialgia Assessment Scale (FAS 2019mod), and Polysymptomatic Distress (PDS) in order to distinguish five levels FM disease severity.Consecutive patients were evaluated with three clinimetric indices, each patient was required answer anchor question: 'In general, would you say your health is 1 = very good, 2 3 fair, 4 poor, or 5 poor?'-which represented external criterion....

10.1093/rheumatology/keaa355 article EN Lara D. Veeken 2020-05-27

Background: We provide the first prospective longitudinal multicenter experience on Upadacitinib efficacy and safety profile in Rheumatoid Arthritis (RA) a real-life context, focusing clinimetric ultrasonographic (US) data. Methods: RA patients referred to three Italian tertiary Centers who started were enrolled as per ACR/EULAR classification criteria prospectively reviewed. The primary aim of this study was assess changes scores through time (at baseline, after 1 month, 3 months, 6 months...

10.3390/jcm13020401 article EN Journal of Clinical Medicine 2024-01-11

Juvenile Localized Scleroderma (JLS) causes functional disabilities and cosmetic deformities. Evaluation follow-up of lesions are mandatory to understand the disease evolution. The objective this study is evaluate usefulness skin ultrasonography (US) in monitoring response treatment JLS.Ten patients (age: 101,7 ± 66,2 months; 7 M, 3 F) affected by juvenile onset LS underwent sequential US exams (at baseline after 6 months). Skin thickness was measured using high-frequency (18 MHz). All were...

10.3109/14397595.2013.844301 article EN Modern Rheumatology 2013-10-18

Mycophenolate mofetil (MMF) has proved to be an efficacious and safe therapy in adult lupus nephritis. Recently, this drug been suggested as a possible new alternative treatment also for juvenile-onset SLE (juvenile-SLE). A multicenter study performed evaluate the efficacy safety of MMF controlling disease activity children adolescents with juvenile-SLE. Our results show that was effective reducing or steroid-sparing agent 14 26 patients (54%), stabilised 8 (31%) ineffective 4 (15%). In...

10.1177/0961203308094999 article EN Lupus 2009-01-16

Switching from originator to biosimilar is part of current practice in inflammatory rheumatic musculoskeletal diseases (iRMDs) such as rheumatoid arthritis (RA), psoriatic (PsA) and axial spondylarthritis (axSpA), with evidences derived both etanercept (ETN) SB4-switching randomized controlled trials real-life registries. We investigated the safety treatment persistence ETN/SB4 a multi-iRMD cohort two rheumatology departments our region.Adult patients iRMDs, treated ETN for at least 6 months...

10.1177/1759720x20964031 article EN Therapeutic Advances in Musculoskeletal Disease 2020-01-01

Various studies have shown that overweight and obesity are central features of FM, but the real impact a high BMI on clinical severity in patients with FM is still controversial. The aim this study was to analyse relationships between categories measures symptom functional impairment using data from Web-based registry FM.Adult an ACR 2010/2011 diagnosis underwent complete physical examination laboratory tests were asked package questionnaires covering their sociodemographic treatment...

10.1093/rap/rkab015 article EN cc-by Rheumatology Advances in Practice 2021-01-01

Balneotherapy (BT) is considered an effective, non-pharmacological approach, in the multimodal treatment of Primary Fibromyalgia Syndrome (FS). However, evidence efficacy and tolerability BT FS still limited. This a prospective multi-center two-cohort observational study. The main aim will be comparison Minimal Clinically Important Difference (according to Impact Questionnaire-FIQ) achievement patients treated with vs standard care. Secondary objectives assess: a) impact on pain, quality...

10.1007/s00484-025-02876-w article EN cc-by International Journal of Biometeorology 2025-03-05

In systemic sclerosis (SSc), dermal capillaries are progressively lost with consequent chronic tissue hypoxia insufficiently compensated by angiogenesis. Clinical studies reported that intravenous cyclophosphamide (CYC) may improve SSc-related peripheral microvascular damage. Recently, we showed CYC treatment normalize SSc sera-induced abnormalities in endothelial cell-matrix interactions. Our objective was to evaluate vitro the effects of sera from treatment-naïve or CYC-treated patients on...

10.1371/journal.pone.0130166 article EN cc-by PLoS ONE 2015-06-15

Background: Oral glucocorticoids (GCs) have been shown to be effective in reducing the inflammatory symptoms of rheumatoid arthritis, but their use is not supported by evidence spondyloarthritis (SpA). Modified-release (MR) oral prednisone taken at bedtime has more than immediate-release morning. The efficacy low-dose MR prednisolone patients with SpA unknown. Patients and methods: This single-center cohort study retrospectively assessed effectiveness safety 12-week (5 mg daily,...

10.2147/dddt.s115099 article EN cc-by-nc Drug Design Development and Therapy 2016-11-01
Coming Soon ...